|
|
|
|
|
|
Sponsors and Collaborators: |
M.D. Anderson Cancer Center Sanofi-Synthelabo |
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00353145 |
Primary objectives:
Secondary objectives:
Condition | Intervention | Phase |
Unknown Primary Neoplasms |
Drug: Gemcitabine (Gemox) Drug: Oxaliplatin Behavioral: Questionnaire |
Phase II |
MedlinePlus related topics: | Cancer |
Drug Information available for: | Gemcitabine hydrochloride Gemcitabine Oxaliplatin |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Study to Evaluate the Efficacy and Toxicity of Oxaliplatin in Combination With Gemcitabine as First and Second Line Therapy in Unknown Primary Cancer |
Estimated Enrollment: | 81 |
Study Start Date: | February 2004 |
Show Detailed Description |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Texas | |||||
U.T. M.D. Anderson Cancer Center | |||||
Houston, Texas, United States, 77030 |
M.D. Anderson Cancer Center |
Sanofi-Synthelabo |
Principal Investigator: | Gauri R. Varadhachary, MD | M.D. Anderson Cancer Center |
Study ID Numbers: | 2003-0946 |
First Received: | July 13, 2006 |
Last Updated: | July 10, 2007 |
ClinicalTrials.gov Identifier: | NCT00353145 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|